

Vaccine Technology VI

An ECI Conference Series Volume 16AA

Albufeira, Portugal
12-17 June 2016

Editors:

**Laura A Palomares
Manon Cox**

**Tarit Mukhopadhyay
Nathalie Garcon**

ISBN: 978-1-5108-3243-5

Printed from e-media with permission by:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571



Some format issues inherent in the e-media version may also appear in this print version.

Copyright© (2016) by Engineering Conferences International
All rights reserved.

Printed by Curran Associates, Inc. (2017)

For permission requests, please contact Engineering Conferences International
at the address below.

Engineering Conferences International
32 Broadway, Suite 314
New York, NY 10004
USA

Phone: (212) 514-6760
Fax: (212) 514-6030

info@engconfintl.org

Additional copies of this publication are available from:

Curran Associates, Inc.
57 Morehouse Lane
Red Hook, NY 12571 USA
Phone: 845-758-0400
Fax: 845-758-2633
Email: curran@proceedings.com
Web: www.proceedings.com

Sunday, June 12, 2016

16:00 - 18:30	Conference check-in
18:30 - 19:30	<u>Opening Keynote</u> Vaccines: Reaching for higher branches after the low hanging fruit has been picked 237 Michael Kurilla, National Institute of Allergy and Infectious Diseases (NIAID), USA
19:30 - 21:00	Dinner

NOTES

- Technical Sessions will be held in Sala Grande Real.
- Poster Sessions will be held in Grande Real Foyer.
- Most meals will be in the Restaurante do Real. Changes will be announced.
- The conference banquet on Thursday will be held in the Restaurante Santa Eulalia.
- Audiotaping, videotaping and photography of presentations are prohibited.
- Speakers – Please leave at least 5 minutes for questions and discussion.
- Please do not smoke at any conference functions.
- Turn your cellular telephones to vibrate or off during technical sessions.
- After the conference, ECI will send an updated participant list to all participants. Please check your listing now and if it needs updating, you may correct it at any time by logging into your ECI account.
- Please do not smoke at any conference functions.
- Please write your name in the front of this program booklet so it can be returned if misplaced.

Monday, June 13, 2016

- 07:30 - 08:30 Breakfast buffet
- 08:30 – 10:30 **Session I: Break Through Developments in Vaccinology**
Chairs: Florian Krammer, The Mount Sinai Hospital, USA, and Hari Pujar, Moderna Therapeutics, USA
- 08:30 – 09:00 **A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in ferrets** 1
Raffael Nachbagauer, Icahn School of Medicine at Mount Sinai, USA
- 09:00 – 09:30 **Single-cell analysis of Influenza A virus-infected cells for the optimization of cell culture-based vaccine production** 2
Sascha Young Kupke, Max Planck Institute for Dynamics of Complex Technical Systems, Germany
- 09:30 – 10:00 **Development of Typhax, a *Salmonella* Typhi Vi polysaccharide protein capsular matrix vaccine** 3
Kevin P. Killeen, Matrivax R&D Corp, USA
- 10:00 – 10:30 **Quantitative, molecular-level analysis of the serum antibody repertoire reveals unanticipated features of the response to seasonal influenza vaccination** 17
Jiwon Lee, The University of Texas at Austin, USA
- 10:30 - 11:00 Coffee break (*Sponsored by Applikon Biotechnology B.V.*)
- 11:00 – 13:00 **Session II: Issues and Case Studies in Process Development**
Chairs: Udo Reichl, Max Planck, Germany and Charles Lutsch, Shantha Biologics, India
- 11:00 – 11:24 **Upstream and downstream process development of a Vero cell-based yellow fever vaccine** 18
Leda R. Castilho, Federal University of Rio de Janeiro (UFRJ), Brazil
- 11:24 – 11:48 **Fast-track lentiviral vector upstream process development: Leveraging high-throughput process monitoring, single-use bioreactor scalability** 19
Nicolas Sève, Sanofi Pasteur, France
- 11:48 – 12:12 **Hollow fiber-based high-cell-density and two-stage bioreactor continuous cultivation: Options and limits towards process intensification for virus production** 20
Yvonne Genzel, Max Planck Institute for Dynamics of Complex Technical Systems, Germany
- 12:12 – 12:36 **A live attenuated RSV vaccine, process development studies** 21
Yvonne E. Thomassen, Intravacc, Netherlands
- 12:36 – 13:00 **Genetic engineering of vaccine manufacturing cell lines enhances poliovirus and enterovirus 71 production** 22
Jon M. Karpilow, Proventus Bio, USA
- 13:00 - 14:00 Lunch

Monday, June 13, 2016 (continued)

- 14:00 - 15:30 **Workshop I: Are regulatory hurdles limiting vaccine manufacturing innovation?**
Facilitators: Katey Owen, The Bill and Melinda Gates Foundation, USA and David 23
Robinson, Robinson Vaccines and Biologics LLC, USA
- 15:30 - 16:00 *Ad hoc* discussions/networking time
- 16:00 - 18:00 **Session III: Formulating and Delivering Vaccines**
Chair: David Volkin, University of Kansas, USA
- 16:00 – 16:30 **Adjuvants in preclinical and clinical development: The do and don't**
Nathalie Garçon, BIOASTER Technology Research Institute, France 24
- 16:30 – 17:00 **Combining DOE with an empirical approach to improve vaccine formulation
development 25**
Jill Livengood, Takeda, USA
- 17:00 – 17:30 **Development of a thermostable ID93 + GLA-SE vaccine using a design of
experiments (DOE) approach 43**
Ryan M. Kramer, Infectious Disease Research Institute (non-profit), USA
- 17:30 – 18:00 **Controlled, pulsatile release of thermostabilized inactivated polio vaccine from
PLGA-based microspheres 44**
Stephany Y. Tzeng, Massachusetts Institute of Technology, USA
- 18:00 - 20:00 Dinner
- 20:00 - 22:00 **Poster Session I with Social Hour**
Chairs: Valerie Mermall, Protein Sciences, USA, Ruth Pastor, UNAM, Mexico, Antonio
Roldao, IBET, Portugal

Tuesday, June 14, 2016

- 07:30 - 08:30 Breakfast buffet
- 08:30 – 10:30 **Session IV: Therapeutic Vaccines**
Chairs: Jean Boyer, Inovio, USA, and Tarit Mukhopadhyay, University College London, United Kingdom
- 08:30 – 09:00 **Current technologies for advancing HIV vaccines 62**
Vadim Tsvetnitsky, IAVI, USA
- 09:00 – 09:30 **Applications of DNA vaccine technology towards difficult immune targets 63**
David Weiner, University of Pennsylvania, USA
(Lecture sponsored by Vaccine Journal (Elsevier))
- 09:30 – 10:00 **Advancing the mRNA therapeutics platforms for vaccines 64**
Hari Pujar, Moderna Therapeutics, USA
- 10:00 – 10:30 **Vaccine based immunotherapy regimen (VBIR) for the treatment of prostate cancer 65**
Helen Cho, Pfizer, USA
- 10:30 - 11:00 Coffee break (*Sponsored by GE Healthcare*)
- 11:00 - 12:00 **Keynote lecture**
Development of immunotherapeutic immunizations for virus infections and cancer 66
Ian Frazer, University of Queensland, Australia
- 12:00 - 13:30 **Workshop II: Academy-Industry Interactions for Advancing in Vaccine Development**
Facilitators: Alex Xenopoulos, EMD Millipore, USA and Manuel JT Carrondo, IBET, Portugal
- 14:00 - 19:30 Pick up boxed lunch
- Boat excursion and guided tour of Faro
- 19:30 Dinner on your own

Wednesday, June 15, 2016

- 07:30 - 08:30 Breakfast buffet
- 08:30 - 10:30 **Session V: Getting Vaccines to the Market: Case studies** 229
Chair: Rebecca Sheets, Grimaltkin Partners, USA and Danilo Casimiro, Aeras, USA
- 08:30 – 09:00 **RSV vaccines for the young and the old** 67
Albert E. Price, MedImmune, USA
- 09:00 – 09:30 **Development, manufacturing, and supply of MSD’s Ebola vaccine** 68
Jeffrey T. Blue, Merck Sharp & Dohme Corp., USA
- 9:30 – 10:00 **Third generation vaccine for world eradication of poliomyelitis** 86
Emilie Rodrigues, Intravacc, Netherlands
- 10:00 – 10:30 **Improving global human health through norovirus virus-like particle manufacturing** 87
Scot Shepard, Takeda Vaccines, USA
- 10:30 - 11:00 Coffee break (*Sponsored by Medimmune*)
- 11:00 - 12:00 **Keynote Lecture**
How is vaccine R&D pipeline strategy going to evolve for pharm industry...? 100
Johan Van Hoof, Janssen Research and Development, Belgium
- 12:00 - 13:00 *Ad hoc* discussions / networking
- 13:00 - 14:00 Lunch
- 14:00 - 15:30 **Workshop III: Vaccine Design and Evaluation - The iVAX Toolkit**
Facilitator: Frances Terry, EpiVax, USA
- 15:30 - 17:00 *Ad hoc* discussions / networking
- 17:00 – 18:00 **Session II: Issues and Case Studies in Process Development (continued)**
Chair: Udo Reichl, Max Planck, Germany and Charles Lutsch, Shantha Biologics, India
- 17:00 – 17:20 **Challenges in the development and scale-up of a purification process for an attenuated live virus vaccine candidate** 101
Matthew Woodling, Merck & Co., Inc., Pennsylvania, USA
- 17:20 – 17:40 **Insect cells platforms for fast production of Pseudo-Typed VLPs for drug and vaccine development** 102
Antonio Roldao, IBET, Portugal
- 17:40 – 18:00 **Determining whether adsorption state is a critical attribute in aluminum adjuvanted vaccines** 103
Garry Morefield, VaxForm, USA
- 18:00 - 20:00 Dinner

Wednesday, June 15, 2016 (continued)

20:00 - 22:00

Poster session II and Social Hour

Chairs: Valerie Mermall, Protein Sciences, USA, Ruth Pastor, UNAM, Mexico,
Antonio Roldao, IBET, Portugal

Thursday, June 16, 2016

- 07:30 - 08:30 Breakfast buffet
- 08:30 – 10:30 **Session VI: Vaccine Characterization and Analytics**
Chairs: Linda Lua, University of Queensland, Australia, and Indresh Srivastava, Protein Sciences, USA
- 08:30 – 09:00 **Analytical characterization of human Cytomegalovirus vaccine and vaccine induced humoral responses** 110
Sha Ha, Merck & Co., Inc., Pennsylvania, USA
- 09:00 – 09:30 **Multi-tasking an inactivated influenza vaccine to provide rapid innate immune-system mediated protection and subsequent long-term adaptive immunity against influenza and secondary pneumococcal infections** 111
Brendon Y. Chua, The University of Melbourne, Australia
- 09:30 – 10:00 **Correlations of antibody response phenotype to genotype revealed by molecular amplification fingerprinting** 112
Sai Reddy, ETH Zurich, Switzerland
- 10:00 – 10:30 **Immune engineering enhances H7N9 vaccine immunogenicity by regulatory T cell epitope deletion in hemagglutinin** 113
Annie De Groot, EpiVax, Inc., Institute for Immunology and Informatics, University of Rhode Island, USA
- 10:30 - 11:00 Coffee break (*Sponsored by Pfizer*)
- 11:00 – 13:00 **Session VII: One World, One Health**
Chairs: Jean-Christophe Audonnet, Merial, France, Juan Garza, UNAM, Ab Osterhaus, University of Veterinary Medicine Hannover, Germany
- 11:00 – 11:30 **Vaccination as a tool to reduce antimicrobial resistance worldwide** 114
Bernard Vallat, OIE, France
- 11:30 – 11:55 **Structural-based designed modular capsomere comprising HA1 as low-cost poultry influenza vaccine** 129
Jarurin Waneesorn, The University of Queensland, Australia
- 11:55 – 12:20 **Development of a vaccine based on recombinant subunit proteins to protect humans and animals against filovirus disease** 130
Axel T. Lehrer, University of Hawaii, USA
- 12:20 – 12:40 **How to deliver new vaccines under very short timelines: The ZAPI project** 131
Jean Christophe Audonnet, Merial, France
- 12:40 – 13:00 **From virus discovery to intervention** 139
Ab Osterhaus, University of Veterinary Medicine Hannover, Germany
- 13:00 - 14:00 **Poster session I with Grazing Lunch**
Chairs: Valerie Mermall, Protein Sciences Corporation, USA, Ruth Pastor, UNAM, Mexico, Antonio Roldao, IBET, Portugal

Thursday, June 16, 2016 (continued)

- 14:00 - 15:00 **Poster session II with Grazing Lunch**
Chairs: Valerie Mermall, Protein Sciences Corporation, USA, Ruth Pastor, UNAM, Mexico, Antonio Roldao, IBET, Portugal
- 15:00 - 16:00 Ad hoc discussions / Networking
- 16:00 - 19:00 **Session VIII: New Challenges and Technologies in Vaccine Development**
Chairs: Albert Price, MedImmune, USA and Odile Leroy, European Vaccine Initiative, Germany
- 16:00 – 16:25 **Systems biology and single cell approaches to study human immune responses to vaccination** 140
John Tsang, NIAID, USA
- 16:25 – 16:50 **Structure-based Vaccine Design: Lessons from RSV F** 141
Jason McLellan, Geisel School of Medicine at Dartmouth, USA
- 16:50 – 17:15 **Induction of antigen-specific immune tolerance with synthetic nanoparticle vaccines** 142
Petr Ilynskii, Selecta Biosciences, USA
- 17:15 – 17:45 **Universal and in-process analytical tool for Influenza quantification using a label-free technology** 143
Sofia Carvalho, iBET/ITQB, Portugal
- 17:45 - 18:10 Coffee break
- 18:10 – 18:35 **Applications of high-throughput single B-cell sequencing to accelerate rational vaccine design** 144
Brandon J. DeKosky, Vaccine Research Center / NIAID, USA
- 18:35 – 19:00 **Plant-based technologies to enable rapid response to Ebola outbreak** 145
Jerzy Karczewski & Vidadi Yusibov, Fraunhofer USA, USA
- 19:00 - 20:00 **Closing Keynote**

Katey Owen, Deputy Director, Vaccines Development CMC, The Bill & Melinda Gates Foundation, USA
- 20:00 - 22:00 Conference Banquet

Poster Presentation List

1. **Influenza vaccine production using cell culture with microcarriers 158**
Alex Xenopoulos, EMD Millipore, USA
2. **Evaluation and scale-up of single-use bioreactors for the production and harvesting of a hepatitis C vaccine candidate 159**
Alex Xenopoulos, EMD Millipore, USA
3. **Computational fluid dynamics modeling for HPV fermentation bioreactors 160**
Tracie Spangler, Merck, USA
4. **Development of a stabilized trimer pre-fusion RSV F recombinant viral glycoprotein vaccine 161**
Richard M. Schwartz, NIAID, NIH, USA
5. **Optimization of sulfated cellulose membrane adsorbers for the purification of influenza virus 162**
A. Raquel Fortuna, Max-Planck Institute for Dynamics of Complex Technical Systems, Germany
6. **Purification of cell culture-derived influenza virus via continuous chromatography 163**
Laura M. Fischer, Max Planck Institute for Dynamics of Complex Technical Systems, Germany
7. **Optimization and scale-up of cell culture and purification processes for production of an adenovirus-vectored tuberculosis vaccine candidate 164**
Aziza Manceur, National Research Council, Canada
8. **Pan-HA antibodies for influenza detection and quantification 165**
Aziza Manceur, National Research Council, Canada
9. **High titer production of HIV-1 virus-like particles by CAP-T cells 166**
Sonia Gutiérrez-Granados, Universitat Autònoma de Barcelona, Spain
10. **Characterization of HA and NA-containing VLPs produced in suspension cultures of HEK 293 cells. 167**
Amine Kamen, McGill University, Canada
11. **Novel avian DuckCelt™-T17 cell line for production of viral vaccines : application to influenza viruses production. 176**
Emma Petiot, Université Claude Bernard Lyon 1 - CIRI, France
12. **Pseudo-affinity purification and formulation of a cell-culture derived whole influenza virus vaccine using magnetic sulfated cellulose particles 177**
Michael Martin Pieler, Max Planck Institute for Dynamics of Complex Technical Systems, Germany
13. **Trumenba: A case study for development of a drug substance manufacturing process through commercialization 178**
Khurram Sunasara, Pfizer, USA
14. **A stabilized subunit vaccine for ebola virus 179**
Keith Chappell, University of Queenslandcular Bioscience, Australia

15. **Improved seed train strategy applied to PER.C6® cells for manufacturing readiness in vaccines production 180**
Piergiuseppe Nestola, Janssen Vaccines AG, Switzerland
16. **History and development of a liquid formulation for adenoviral vaccines 181**
Lara Babich, Janssen Infectious Diseases & Vaccines, Netherlands
17. **Tetraspanins displayed in retrovirus-derived virus-like particles and their impact in vaccine development 182**
Hugo R. Soares, iBET, Portugal
18. **Insect Cells Platforms for efficient production of multi-HA Influenza VLP-based vaccines 183**
António Roldão, Instituto de Biologia Experimental e Tecnológica (iBet), Portugal
19. **Improving downstream processing of enveloped virus-like particles with multi-column chromatography 184**
Ricardo Silva, iBET, Portugal
20. **A click chemistry strategy to specifically monitor and improve purification of Influenza virus-like particles 185**
Sofia Carvalho, iBET/ITQB, Portugal
21. **Enveloped virus-like particles purification using an all-filtration technology platform 186**
Sofia Carvalho, IBET/ITQB-UNL, Portugal
22. **The papaya mosaic virus (PapMV) nanoparticles; a promising tool in vaccine development. 187**
Denis Leclerc, U Laval, Canada
23. **Novel pulsatile-release microparticles for single-injection vaccination 188**
Stephany Y. Tzeng, Massachusetts Institute of Technology, USA
24. **Structurally confined influenza subunit vaccines in the prefusion conformation elicit a potent neutralizing antibody response 189**
Daniel Watterson, University of Queensland, Australia
25. **Vaccination with recombinant neuraminidase protects against influenza virus infection in mice 190**
Teddy John Wohlbold, Icahn School of Medicine at Mount Sinai, USA
26. **Residual DNA analysis in influenza vaccine processing 191**
Camilla Estmer Nilsson, GE Healthcare, Sweden
27. **Study of rabies VLPs expression in BHK-21 cell line for vaccine applications 192**
Claudio Prieto, Universidad Nacional Del Litoral, Argentina
28. **Expression of rabies VLPs in adherence and suspension conditions: a flexible platform for rabies vaccine production 193**
Diego Fontana, Universidad Nacional Del Litoral, Argentina
29. **Process economy effects of modernizations in vaccine purification 194**
Mia Bennemo, GE Healthcare Life Sciences, Sweden
30. **Propagation of influenza and MVA virus in cascades of continuous stirred tank bioreactors: challenging the "Von Magnus effect" 195**
Felipe Tapia, Max Planck Institute Magdeburg, Germany

31. **Intensification of MVA and influenza virus production through high-cell-density cultivation approaches 196**
Daniel Vazquez, Max Planck Institute, Magdeburg, Germany
32. **Production of a Nanoplasmid™ with a large gene insert using the HyperGRO™ fermentation process N/A**
Aaron Carnes, Nature Technology Corporation, USA
33. **Virus-like particles adsorption in anion exchange chromatography media 197**
Patricia Pereira Aguilar, University of Natural Resources and Life Sciences Vienna (BOKU), Austria
34. **Ready to use gamma irradiated microcarriers for virus production in single use bioreactor systems 198**
Gustaf Ahlén, GE Healthcare Biosciences, Sweden
35. **Development of a versatile vaccination platform based on papaya mosaic virus (PapMV) nanoparticles 199**
Ariane Therien, Université Laval, Canada
36. **Evaluation of producer cell lines for yellow fever virus production in up to 1 L bioreactor scale 200**
Alexander Nikolay, Max Planck Institute for Dynamics of Complex Technical Systems, Germany
37. **Propagation of Brazilian Zika virus strains in static, microcarrier-based and suspension cultures using BHK and Vero cells 201**
Alexander Nikolay, Max Planck Institute for Dynamics of Complex Technical Systems, Germany
38. **Electron microscopy as an emerging analytical tool for characterizing vaccines 202**
Anette Schneemann, Nanolmaging Services Inc, USA
39. **Optimizing scale-up of Vero cells cultured on microcarriers in serum-free medium for vaccine production 203**
Anna-Barbara Hachmann, Thermo Fisher Scientific, USA
40. **Custom open polyethersulfone ultrafiltration membranes for vaccines 204**
Clifton Ngan, MilliporeSigma, USA
41. **Highly cross-conserved burkholderia T cell epitopes generate effector T cell responses in vitro 205**
Annie De Groot, EpiVax.Inc; University of Rhode Island, USA
42. **Predicting tolerance in vaccine antigens: Application to influenza, HCV and HIV 206**
Annie De Groot, EpiVax, Inc; University of Rhode Island, USA
43. **In vivo validation of predicted and conserved T cell epitopes in a swine influenza model 207**
Anne De Groot, EpiVax.Inc., USA
44. **Development of insect cell platforms for fast production of pseudo-typed VLPs for drug and vaccine development 208**
João Vidigal, iBET, Portugal

45. **Safe and green, the hyperbar inactivation 209**
Fabien Lux, Sanofi Pasteur, France
46. **Influenza A virus propagation in MDCK: Intracellular virus replication, virus release and cell-cycle preferential infection analysis 210**
Lilí E. Gallo, Max Planck Institute for Dynamics of Complex Technical Systems, Germany
47. **VP2 potentiates the protection induced by VP6 against the rotavirus infection in a DNA vaccine model 211**
Vanessa D. López-Guerrero, UAEM, Mexico
48. **Differential antibody response against conformational and linear epitopes of the L1 protein from human papillomavirus types 16/18 is generated in vaccinated woman or with different exposures to the virus 212**
Lourdes Gutierrez-Xicotencatl, National Institute of Public Health, Mexico
49. **N-Glycosylation affects humoral immune response of Her1 cancer vaccine 213**
Adolfo Castillo Vitloch, Center of Molecular Immunology, Cuba
50. **IL-17A and *Streptococcus pneumoniae* respiratory infection: Prospects for the development of new immunotherapies 214**
Analía Rial, Universidad de la República, Uruguay
51. **Transferring methods for vaccine release between the industry, academy and a regulatory agency: Lessons learned 215**
Elizabeth Carrasco, Instituto de Biotecnología-UNAM, Mexico
52. **Unmasking stem-specific broadly neutralizing epitopes by abolishing N-linked glycosylation sites for vaccine design 216**
Suh-Chin Wu, National Tsing Hua University, Taiwan
53. **Improved diagnostics and surveillance identify novel reassortant swine influenza A viruses in Chile 217**
Rafael A. Medina, Pontificia Universidad Católica de Chile, Chile
54. **First characterization of immunogenic conjugates of vi negative salmonella typhi O-specific polysaccharides with rEPA protein for vaccine development 218**
Muhammad Salman, AWKUM, Pakistan
55. **Development of a production process for a recombinant protein pneumococcal vaccine N/A**
Ana Maria Pereira dos Santos, Bio-Manguinhos, Brazil
56. **Development of a high yield purification process for the production of influenza virus vaccines 219**
Hyung-Jin Jeon, Green Cross Corporation, South Korea
57. **Simple and robust downstream purification process for cell-derived influenza vaccines 220**
Yu-Fen Tseng, National Health Research Institutes, Taiwan
58. **SynGEM: An intranasal prefusion-like RSV F subunit vaccine 221**
Maarten L. van Roosmalen, Mucosis, Netherlands

59. **Challenges in the construction of a multi-product vaccine facility 222**
Rachel Appetiti, Sanofi Pasteur, France
60. **Longitudinal landscapes of serum antibody repertoires after influenza infection and vaccination 223**
Jiwon Lee, The University of Texas at Austin, USA
61. **Microcarrier-based production of dengue virus in animal-free medium 224**
Mark Szczypka, Pall Corporation, USA
62. **Increasing process productivity for an antibody-based cancer vaccine 225**
Ernesto Chico, Center of Molecular Immunology, Cuba
63. **Pathogen genetic diversity a challenge for vaccine development: Looking for the pathogen's Achilles' heel 226**
Ousmane A. Koita, University of Science, Techniques and Technologies of Bamako, Mali
64. **Finding the missing link in single use fermentation line : Evaluation of single use bioreactors for aerobic bacteria 227**
Marie Izac, Sanofi Pasteur, France
65. **Metabolic drivers of IC-BEVS productivity: Tackling the production of enveloped viral particles 228**
João Vidigal, iBET, Portugal
66. **Immunization with surface immunogenic protein induces a decrease of vaginal colonization by group B Streptococcus in an experimental mouse model N/A**
Jorge A. Soto, Instituto De Salud Publica DeChile, Chile